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Cardiac Imaging Modalities With
Ionizing Radiation
The Role of Informed Consent
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Informed consent ideally results in patient autonomy and rational health care decisions. Frequently,
patients face complex medical decisions that require a delicate balancing of anticipated beneﬁts and
potential risks, which is the concept of informed consent. This balancing process requires an understanding
of available medical evidence and alternative medical options, and input from experienced physicians. The
informed consent doctrine places a positive obligation on physicians to partner with patients as they try to
make the best decision for their speciﬁcmedical situation. The high prevalence andmortality related to heart
disease in our society has led to increased cardiac imaging with modalities that use ionizing radiation. This
paper reviews how physicians can meet the ideals of informed consent when considering cardiac imaging
with ionizing radiation, given the limited evidence for risks and beneﬁts. The goal is an informed patient
making rational choices based on available medical information.c
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he United States currently does not
have national guidelines for informing
patients about potential risks of exposure
to diagnostic medical radiation. Con-
ersely, the European Union has codified into
aw that one who refers a patient for a radio-
ogical examination must provide “sufficient
edical data” to justify the study (1–3). U.S.
hysicians have a fiduciary duty to obtain
nformed consent from patients before per-
orming any procedure or assume the risk of
edical negligence. Legally, “a fiduciary is
omeone who has undertaken to act for and on
he behalf of another in a particular matter or
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November 10, 2011, accepted November 21, 2011.ircumstances that gives rise to a relationship of
rust and confidence” (4). Furthermore, for a
atient’s consent to be valid under law, the
atient must be given sufficient information to
nderstand the risks and benefits to make a
ully informed decision (5).
The evolving medical literature, U.S. Food
nd Drug Administration (FDA) news releases
bout reduction of unnecessary radiation, and
ouse of Representatives initiatives to regulate
edical radiation have focused the attention of
he public, the media, and health care providers
n the controversy surrounding the risk of
alignancies related to medical imaging with
onizing radiation (6 –10). The debate on
hether it is necessary to inform patients of
hese potential risks prior to performing imag-
ng with ionizing radiation is a corollary to this
ontroversy (11). This corollary has become a
ocal concern for physicians, risk managers, and
nsurers given a recent ruling by the Wisconsin
ourt of Appeals, recently affirmed by the
isconsin Supreme Court, in Jandre v. Physi-
t
m
a
o
d
l
s
s
m
t
c
“
p
r
m
n
d
c
r
n
a
o
t
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 3 4 – 4 0
Paterick et al.
Informed Consent and Diagnostic Medical Radiation
635cians Insurance Company of Wisconsin
(12). The debate is “heated” because of
the uncertainty and complexity sur-
rounding the underlying issues, and the
many possible unintended conse-
quences on patient outcomes and phy-
sicians’ workloads. In this paper, we
discuss why physicians ordering tests
that use ionizing radiation have a fidu-
ciary responsibility to their patients to
provide available medical risk/benefit
data and alternative approaches to
treatment, and obtain informed con-
sent. This fiduciary responsibility has
ethical and legal underpinnings. On the
basis of these concepts, we outline a
logical and linear approach to informed
consent before cardiac imaging with
ionizing radiation.
Use of Medical Imaging
and Informed Consent
Utilization of medical imaging has
grown exponentially in recent years
(13,14). For example, the volume of
nuclear myocardial perfusion imaging
(MPI) has increased from 3 million
procedures in the United States in 1990
to 9.3 million in 2002 (15). This in-
creased medical radiation burden has
raised public health concerns about
possible malignancy rate increases in
the future, and led to an FDA initiative
(9,10) and a discussion in Congress of
new legislation to regulate medical ra-
diation (10). Recent studies revealed
repeat testing with nuclear MPI to be
common and, in many patients, associ-
ated with high cumulative doses of
radiation (6,16,17). Some studies sug-
gested that the use of computed to-
mography (CT) and nuclear MPI may
be associated with 1.5% to 2.0% of all
future cancers (18,19), and serial test-
ing with ionizing radiation is associated
with a noticeable increase of projected
cancer risk in patients with acute myo-
cardial infarction (20).
By contrast, there may be a lack of
awareness among health care providers
and patients regarding the probability
of potential risks of ionizing radiation
and the concepts of radiation protec-tion. The courts have declared a
“prudent-person standard,” in which
any risk from an investigation or treat-
ment must be communicated if a rea-
sonable person would want to know
that information to determine whether
to proceed (21–25). The medical liter-
ature suggests the informed consent
process is sporadic, at best, at ensuring
patients are informed about the risks
and benefits of diagnostic ionizing ra-
diation. Although most academic med-
ical centers have guidelines about ob-
taining informed consent before CT,
only a minority of these institutions
follow through with providing infor-
mation on potential radiation risks and
alternative approaches to patients (2).
Most physicians do not know whether
patients at their institutions are in-
formed about potential cancer risk from
ionizing radiation, but do believe that
informing them about it is important
(2,26). However, most physicians, in-
dependent of their experience level,
cannot provide reasonable estimates for
the radiation doses associated with pro-
posed diagnostic testing (27). A recent
study found that more than 90% of
patients were not informed of any ra-
diation risk prior to CT (27). The
prevailing opinion in medicine and law
emphasizes the need to inform patients
about the potential risks of ionizing
radiation while obtaining informed
consent, and the need to implement
pragmatic strategies to achieve that
goal (25,28).
Risks and Benefits of Cardiac Imaging
With Ionizing Radiation
Discussing risks and benefits of cardiac
imaging with patients is difficult be-
cause of the lack of solid evidence that
would suggest disease-management
strategies guided by cardiac imaging
more often lead to better patient out-
comes than empirical medical strate-
gies. Additionally, there is a lack of
direct evidence for harm from low-dose
diagnostic medical radiation (29). Ex-
amples for radiation dose estimates for
contemporary cardiac imaging tests arepresented in Table 1 (30–44). It is
important to recognize that most car-
diac imaging studies across the United
States are probably done on equipment
that is not capable of the latest, most
effective dose-sparing techniques.
Beneﬁts of imaging. Imaging generally
has not been held to the same standard
of rigorous evaluation as have other
aspects of medical care (45). Prospec-
tive, randomized clinical trials that
compare the outcomes of management
strategies with and without imaging
(46,47) are difficult to design and,
hence, rare. In symptomatic patients,
there is a risk of failing to diagnose a
cardiac condition and, thus, improving
quality of life or longevity by not per-
forming an imaging study to avoid
radiation exposure. As a corollary to the
potential benefits of imaging, patients
must be made aware of this important
risk of avoiding diagnostic imaging that
uses ionizing radiation.
Risks of ionizing radiation. At the radia-
ion doses typically used in diagnostic
edical imaging, the risks of morbidity
nd mortality due to malignancy that
ften carry over into the lay press are
erived from epidemiological models
argely based on extrapolations from
urvivors of the atomic bomb explo-
ions in Japan in 1945 (48). To opti-
ally protect the best interests of pa-
ients, current radiation protection
oncepts are based on the so-called
linear no-threshold” model, which
ostulates that any level of ionizing
adiation, however low, can cause a
alignancy, and that the risk of malig-
ancy increases linearly with radiation
ose (49). Controversies about the pre-
ise magnitude of risk for malignancy
elated to low-dose ionizing radiation
otwithstanding, these projected risks
re generally greater for younger than
lder patients, and greater for women
han men.
Doctrine of Medical Informed Consent
How can we translate this background
information effectively into a meaning-
ful practice of obtaining informed con-
N/A
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 3 4 – 4 0
Paterick et al.
Informed Consent and Diagnostic Medical Radiation
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trine of medical informed consent is
2-fold: 1) to establish and promote
patient autonomy; and 2) to promote
informed rational decisions. The courts
hold that it is reasonable to require
physicians to inform, educate, and part-
ner with patients because patients are
generally unable to translate the details
of medical science into making edu-
cated decisions about testing or treat-
ment by themselves (50). This educa-
tional process should inform the
patient sufficiently to allow a rational
decision that reasonably reflects the
possibilities of positive or negative
consequences.
Elements of informed consent. The doc-
trine of medical informed consent
states that before a patient elects to
proceed with a treatment that carries
risks, there must be a balanced discus-
sion of the treatment strategy, includ-
ing potential risks and anticipated ben-
efits (51). Risk can be defined as
exposure to a chance of injury or loss
(14). This definition contains 2 distinct
components: 1) chance related to un-
certain events—those that are unpre-
Table 1. Ionizing Radiation in Cardiac Imaging
Examination
Chest x-ray posteroanterior and lateral
Diagnostic invasive coronary angiogram
Coronary CT angiogram
64-slice multidetector, retrospective gating
64-slice multidetector, reduced tube voltage (1
64-slice multidetector, prospective triggering
Dual-source high pitch
264 or 320 multidetector row CT
Nuclear medicine studies
Myocardial perfusion
Sestamibi (1-day) stress/rest
Tetrofosmin (1-day) stress/rest
Thallium stress/redistribution
Rubidium-82 rest/stress
Myocardial viability
PET F-18 FDG
Thallium stress/reinjection
Table adapted from Mark et al. (30) and Raff (31), with perm
CT  computed tomography; FDG  ﬂuorodeoxyglucose;dictable in any single case, but forwhich a probability that an event will
occur in any 1 case can be estimated
through statistical pooling of large da-
tabases; and 2) injury or loss, including
any consequences by which the patient
sustains a disability.
All physicians have a mandatory ob-
ligation to understand the medical in-
formed consent process. Understanding
the process allows for the exchange of
ideas in medical practice that will yield
informed, high-utility decisions while
limiting the potential for negligence
cases filed for lack of informed consent.
Cardiac imaging with ionizing radia-
tion has anticipated benefits and poten-
tial risks that a patient must understand
to make an informed choice about
whether to undergo such testing. This
risk/benefit analysis is particularly impor-
tant for certain subsets of patients for
whom the risk may exceed the benefit.
Medical informed consent is ethi-
cally, morally, and legally mandated by
the fiduciary responsibilities of the pa-
tient–physician relationship. Negli-
gence “per se” (an automatic finding of
negligence) occurs when an actor’s vi-
olation of a statute or regulation causes
Representative Effective
Dose Value (mSv)
Range
D
0.1
7
12
kVp) 6
3
1
4
12
10
29
10
14
41
n from Elsevier. Data include a survey of the literature since
 not applicable; PET  positron emission tomography.the kind of harm the statute was in-tended to prevent (21,22). Physicians
have a moral responsibility to identify
the best treatments for each patient on
the basis of available medical evidence,
and to discuss with patients the antic-
ipated benefits and potential risks. This
exchange of information and ideas is
the foundation of the patient–physician
partnership and promotes informed
decision-making in the most complex
medical situations. This approach re-
flects physicians’ ethical and moral re-
sponsibilities in patient care, and there
is no easy way out.
What level of disclosure is sufﬁcient?
Historically, the “professional stan-
dard” asserted it was a physician’s duty
to disclose what a reasonably prudent
physician with the same background,
training, and experience would have
disclosed to a patient in the same or
similar circumstances (21–25,50,51).
That standard has evolved, and now a
physician must disclose “what a reason-
able person in the patient’s position
would want to know to make an intel-
ligent decision with respect to the
choices of treatment or diagnosis”
(50,51). The courts stress that “full”
eported Effective
Values (mSv)
Administered Activity
(MBq)
.05–0.24 N/A
2–16 N/A
9–19 N/A
3–8 N/A
2–4 N/A
1 N/A
2–8 N/A
N/A 1,480
N/A 1,480
N/A 130
N/A 2,960
N/A 740
N/A 185
(30–44).of R
ose
0
00
issio 2008disclosure is neither required, nor at-
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burden of identifying minimal conse-
quences of extremely improbable risks
imposes too great a burden on the
physician; and 2) the patient’s choice of
treatment would be impaired by a litany
of potential consequences. However,
even though the courts have pronounced
that “full” disclosure is not required
(21,24), they generally have not defined
how much information less than “full”
disclosure will satisfy informed consent
requirements (21,24). Therefore, there
are no explicit directions on how to
achieve the disclosure standard to
which physicians must adhere to avoid
liability with certainty.
Courts have attempted to provide
guidance for physicians by suggesting
that their duty to disclose risk increases
as the magnitude of risk increases.
However, the courts uniformly fail to
explicitly identify the scale by which
probability and severity of risks are to
be measured (21–25,50,51). Serious
risks (death, paralysis, loss of cognition,
loss of limb, and inducement of cancer)
should always be disclosed, even if the
probability of occurrence is negligible.
Further, less serious risks always should
be disclosed if the probability of occur-
rence is high. Courts do not place
emphasis solely on severity, but recog-
nize probability as an important com-
ponent of risk (50,51).
Medicolegal Implications
of Informed Consent
A recent Wisconsin Court of Appeals
decision reinforces the argument for
broad application of the informed con-
sent requirements and deserves review
(12). The court analyzed this case based
on Wisconsin Statute, Wis. Stat. sec-
tion 448.30, which, in part, provides
that “any physician who treats a patient
shall inform the patient about the avail-
ability of all alternative, viable medical
modes of treatment and about the ben-
efits of these treatments.”
In Jandre v. Physicians Insurance
Company of Wisconsin, the patient was
brought to the emergency department(ED) with complaints of sudden-onset
drooling, slurred speech, left facial
droop, dizziness, balance issues, and leg
weakness. The ED physician noted
left-sided facial weakness and mildly
slurred speech. The physician’s differ-
ential diagnosis included stroke and
Bell’s palsy. The final diagnosis was
Bell’s palsy after physical examination
revealed absence of carotid bruits
(which could have implied ischemic
stroke) and a CT scan of the head
showed no findings suggestive of hem-
orrhagic stroke. The patient was dis-
charged and instructed to follow-up
with his family physician. Eleven days
after the ED visit, the patient suffered a
stroke. Carotid ultrasound performed
at that time revealed 95% stenosis of
the right internal carotid artery.
A jury trial exonerated the physician
on a count of medical negligence for
misdiagnosis. However, the jury ruled,
and the Wisconsin Court of Appeals
and Wisconsin Supreme Court af-
firmed, that the physician violated the
Wisconsin informed consent statute,
and awarded a $1.8 million judgment
to the patient. The Appeals Court af-
firmed that the ED physician’s failure
to inform the patient that his symp-
toms also were consistent with stroke,
and that carotid ultrasound was avail-
able to aid in diagnostic evaluation,
violated the informed consent law. Of
note, the court in its judgment did not
mention embolic stroke as yet another
differential diagnosis for which testing
was not performed. The court reaf-
firmed that the standard of informed
consent is objective, and is defined by
what a reasonable person would want
to know to make an intelligent decision
about testing and treatment. The court
specifically noted that, because a stroke
can severely incapacitate or kill, a rea-
sonable person would want to know of
a test to address the possibility of stroke to
explain his or her symptoms, and to evalu-
ate the physician’s diagnosis and recom-
mended treatment for Bell’s palsy.
In Wisconsin, the state’s Supreme
Court decision extends the reach of theinformed consent doctrine to a very
broad dimension. This case could have
broad implications for the diagnostic ap-
proach to patients, including disclosure of
potential carcinogenicity of diagnostic
medical radiation or, conversely, the pos-
sibility of failing to diagnose a dangerous
condition by foregoing a radiological
examination because of radiation con-
cerns. The Jandre case suggests that
physicians shoulder broad legal respon-
sibility to obtain informed consent, not
only for the procedure or treatment
they are recommending, but also for
other strategies and options for diagno-
sis and treatment. As fiduciary, the
physician performing or supervising the
procedure is legally responsible to in-
form the patient of the risks, benefits,
and viable alternatives to obtain the
best medical care.
TooMuch Effort for Too Little Gain?
Because it is currently not possible to
define a threshold dose of ionizing
radiation or level of radiation-related
cancer risk that absolutely would re-
quire informed consent, prudent physi-
cians will obtain informed consent for all
procedures that use ionizing radiation.
The typical physician counterarguments
that the informed consent process is too
time-consuming and requires too many
resources in busy medical practices, or
that the risk of ionizing radiation is un-
certain and detailed discussions would
only confuse patients, would never en-
dure a legal analysis, and are unlikely to
prevail in a court of law.
The argument that there is no case
law regarding ionizing radiation and
cancer only reflects the fact that most
claims are settled out of court or are
tried but not appealed, meaning there is
no recorded, precedential decision. The
absence of case law does not imply that
legal risk does not exist. The Jandre
court found that Wis. Stat. sec. 448.30
requires a physician to inform a patient
of all alternative viable modes of treat-
ment—including diagnosis—that a
reasonable person in the patient’s posi-
tion would want to know to make an
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treatment or diagnosis. A reasonable
person would want to know the poten-
tial risk of cancer from the use of
ionizing radiation no matter how neg-
ligible the risk, especially when alterna-
tive modes of diagnosis are available
that do not carry such risk.
Elements of Informed Consent for
Diagnostic Medical Radiation Use
The doctrine of informed consent de-
mands that physicians carefully con-
sider whether the benefits outweigh the
risks when testing with ionizing radia-
tion compared with alternative strate-
gies for each individual patient. What
do we share with patients about the
risks and benefits of cardiac imaging to
achieve informed consent based on the
available medical knowledge? The pro-
jected probability and potential severity
of risks should be emphasized candidly.
Also, alternative strategies and their
benefits, risks, and measured utility (the
risks of testing and the probability of a
benefit with the alternative strategy)
versus the primary strategy should be
considered. We propose that a physi-
cian acting as a patient’s fiduciary frame
the risks as follows:
1. The precise magnitude of risk for
malignancy related to low-dose
ionizing radiation is not, and may
never be, known. However, to op-
timally protect the best interests of
the patients, current radiation protec-
tion concepts are based on an assump-
tion that any dose level of ionizing
radiation can cause a malignancy.
2. At the radiation doses typically
used in diagnostic medical imaging,
the cancer risks patients may have
heard about from mass media are
based on extrapolations from survi-
vors of the atomic bomb explosions
in Japan in 1945 who experienced
whole-body exposures to different
types, different energies, and higher
doses of radiation.
3. In a number of studies in which
many subjects were followed formany years, there are no unequivo-
cal, direct confirmations of in-
creased risk for solid cancers related
to low-dose radiation (100 mSv).
4. Projected risks for malignancy from
ionizing radiation are greater for
younger than older patients and
greater for women than men.
5. Cancer resulting from exposure to
ionizing radiation would occur, if at
all, only after a latency period of
several years.
The benefits could be framed as
follows:
1. For symptomatic patients, the po-
tential benefits of imaging include
establishing the presence of cardio-
vascular disease, which allows disease-
specific therapy to improve quality
of life, for example, through relief
of angina symptoms. If imaging
refutes the presence of cardiovascu-
lar disease, medical attention can be
appropriately refocused on noncar-
diac conditions as the cause of symp-
toms. In some symptomatic patients,
imaging may uncover medical condi-
tions for which targeted treatment
will improve survival.
2. Not performing a cardiac imaging
study because of radiation dose
concerns may carry the risk of miss-
ing a condition that could be rem-
edied with the effect of improving
quality of life or longevity.
3. In select asymptomatic patients,
CT for coronary artery calcium
screening may refine prediction of
cardiovascular risk. However, for
most asymptomatic, active patients,
including those considered at high
cardiovascular risk, there are no
proven benefits of cardiac imaging.
The potential alternatives to disclose
include nonimaging approaches such as
electrocardiography, or imaging mo-
dalities that do not use ionizing radia-
tion, such as echocardiography or cardiac
magnetic resonance imaging. Their
availability depends on local expertise
and applicability on the clinical ques-
tion at hand. Some of these alternativesmay not be useful in any given clinical
scenario.
Summary
Given the uncertainty regarding the
carcinogenic potential of ionizing radi-
ation at the doses used for noncontrast
cardiac CT and nuclear cardiology, the
prudent physician should use these im-
aging modalities only when the clinical
benefits can be expected to exceed the
risk, and when the patient understands
that risk/benefit relationship and wishes
to proceed.
From a legal perspective, the bal-
anced discussion between the physician
and the patient about the risks and
benefits mandated by the medical doc-
trine of informed consent (a positive
obligation) should lead to informed
patients who make autonomous choices
based on the best available medical
information. In the specific case of
cardiac imaging with modalities that
use ionizing radiation, informed consent
could reduce the rate of such procedures
in young patients and women except in
those where there are compelling, coun-
tervailing reasons why imaging is the best
diagnostic choice, and in asymptomatic
patients where improvement in quality of
life or survival benefit by cardiac imaging
are not defined.
The absence of case law on cancer
risk related to ionizing radiation does
not imply that no such risk exists, or that
there is no medicolegal liability for the
physician. Informed consent will reduce
the risk of liability for physicians by
carefully balancing risks and benefits and
sharing them with their patients before
proceeding with testing or treatment.
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